Bacterially produced human B7-1 protein encompassing its complete extracellular domain maintains its costimulatory activity in vitro

Chinese Medical Journal

Volumn 113, Issue 8, 2000, Pages 714-719

  Shen, Wenhong ^a   Wang, YiIi ^a   Geng, Yiping ^a   Si, Lüsheng ^a  

^a XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

B7.1 immunoglobulin domain; Human B7 1; T lymphocyte activation

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN;

ARTICLE; BIOSYNTHESIS; CELL DIVISION; CYTOLOGY; ESCHERICHIA COLI; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; PROKARYOTIC CELL; T LYMPHOCYTE;

ANTIGENS, CD3; ANTIGENS, CD80; CELL DIVISION; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; PROKARYOTIC CELLS; T-LYMPHOCYTES;

EID: 0034256398     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-730.
2. Linsley PS, Brady W, Grosmaire L, et al. CTLA-4 is a second receptor for B cell activation antigen B7. J Exp Med 1991;174: 561-569.
3. June CH, Bluestone JA, Nadler LM, et al. The B7 and CD28 receptor famines, Immunol Today 1994;15:321-331.
4. Inobe M, Linsley PS, Ledbetter JA, et al. Identification of an alternatively spliced form of the murine homologue of B7. Biochem Biophy Res Commun 1994;200:443-449.
5. Chen L, Ashe A, Brady WA, et al. Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecule CD28 and CTLA-4. Cell 1992;72:1093-1122.
6. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD28 + T cell by B7-transfected melanoma cells. Science 1993;259:368-370.
7. Ramarathian L, Castle M, Wu Y, et al. T cell costimulation by B7/BB1, induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1, in the induction, recruitment and effector function of antitumor T cell. J Exp Med 1994;179:1205-1214.
8. Finck B, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA-4 Ig. Science 1994;265:1225-1227.
9. Milich D, Linsley PS, Hughes JL, et al. Soluble CTLA-4 can suppress autoantibody production and elicit long term responsiveness in a novel transgenic model. J Immunol 1994;153:429-435.
10. Turka LA, Linsley PS, Lin H, et al. T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 1992;89:11102-11106.
11. Lenschow DJ, Zheng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4 Ig. Science 1992;257:789-792.
12. Freeman GJ, Freedman AS, Segil JM, et al. B7 a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989;43:2714-2722.
13. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin super family CTLA-4. Nature 1987;328:267-270.
14. Peach RJ, Bajorath J, Brady W, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous region in CTLA-4 and CD28 determine the binding to B7-1 (CD80). J Exp Med 1994; 180:2049-2058.
15. Ellis JH, Burden MN, Vinogradov DV, et al. Interaction of CD80 and CD86 with CD28 and CTLA-4. J Immunol 1996;56:2700-2709.
16. Peach RJ, Bajorath J, Naemura J, et al. Both extracellular immunoglobulin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28. J Biol Chem 1995; 270:21181-21187.
17. Guo Y, Wu Y, Zhao M, et al. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA-4 binding site on immunoglobulin C-like domain. J Exp Med 1995;181:1345-1355.
18. Fargeas CA, Truneh A, Reddy M, et al. Identification of residues in the V domain of B7-1 (CD80) implicated in functional interactions with CD28 and CTLA-4. J Exp Med 1995;182:667-675.
19. Inobe M, Aoki N, Linsley PS, et al. The role of B7-1 (CD80) a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation. J Immunol 1996;157:582-588.
20. Zheng P, Wu Y, Guo Y, et al. B7-CTLA-4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge. Proc Natl Acad Sci U S A 1998;95: 6284-6289.
21. Guo Y, Wu Y, Kong X, et al. Identification of conserved amino acids in murine B7-1 IgV domain critical for CTLA-4/CD28: B7 interaction by site-directed mutagenesis: a novel structural model of the binding site. Mol Immunol 1998;35:215-225.
22. Chen A, Meyerson HJ, Salveka A, et al. Non-glycosylated human B7-1 (CD80) retains the capacity to bind its counter-receptors. FEBS Letters 1998;428:127-134.